SS-31 (Elamipretide): What the Evidence Actually Shows

What is SS-31?

SS-31 (also written as elamipretide, Bendavia, MTP-131, or informally as “ss31 peptide” / “ss 31 peptide”) is a synthetic, lab-made tetrapeptide that targets mitochondria directly rather than acting on a cell-surface receptor. It has one FDA-approved use, granted in 2025, for the rare genetic disease Barth syndrome.

Everything else associated with it, including longevity, kidney, cardiovascular, and weight-loss claims, remains investigational.

Chemically, SS-31 is D-Arg-Dmt-Lys-Phe-NH2, a synthetic aromatic-cationic peptide with a molecular weight of 639.8 g/mol. Its small size and structure let it cross into cells and concentrate inside mitochondria, the structures that generate cellular energy, without needing a transporter or receptor to get there.

The compound was originally discovered by researchers Szeto and Schiller while studying opioid receptors. The “SS” in SS-31 stands for Szeto-Schiller, and “31” simply denotes its position among the peptide candidates the pair developed. It was never designed as an opioid drug; further research redirected it toward mitochondrial biology once its cardiolipin-binding properties became apparent.

That distinction matters for understanding what SS-31 actually is. It is not modeled on a hormone, growth factor, or neurotransmitter system the way many other peptides are. It’s built to bind cardiolipin, a phospholipid embedded in the inner mitochondrial membrane, and stabilize mitochondrial structure at a molecular level. This is a structural and functional mechanism, not a receptor-based one.

In practical terms, SS-31’s only regulatory-approved use today is Barth syndrome, a rare genetic mitochondrial disease caused by mutations in the TAFAZZIN gene. The pivotal TAZPOWER trial in human patients supported that approval. Outside that single indication, human data is considerably thinner.

Trials in heart failure and mitochondrial myopathy exist but show mixed or inconclusive results, and claims around longevity, general mitochondrial health, athletic performance, kidney protection, or weight loss are not backed by human trials at all; they draw on animal and preclinical research only.

This is the core gap worth understanding before going further: SS-31’s mechanism, binding cardiolipin and reducing electron leakage at the source, is well-characterized and considered biologically credible by researchers. But mechanism being plausible is not the same as outcomes being proven. The research base reflects that split.

There’s an extensive animal literature, particularly in kidney disease models, a handful of human trials with mixed results in heart failure and myopathy, and exactly one positive, pivotal human program (Barth syndrome/TAZPOWER) that reached approval.

A comprehensive picture of SS-31 has to hold both facts at once: real mechanistic credibility, and real evidence limits everywhere except the one condition it’s actually approved to treat.

What the research shows

Barth syndrome, Moderate evidence, human data: Yes

The clearest human evidence for SS-31 comes from the TAZPOWER trial, a Phase II/III study in Barth syndrome patients that showed measurable functional improvements and became the basis for the 2025 FDA approval, the first regulatory clearance ever granted to a mitochondria-targeted peptide.

This is currently the only use case with regulatory-grade human data behind it.

Heart failure, Limited evidence, human data: Some

Results here are inconsistent across three separate trials. A late-stage HFrEF (heart failure with reduced ejection fraction) trial missed its primary endpoint entirely. A separate HFpEF (preserved ejection fraction) trial showed a signal of improvement in peak VO2, a marker of exercise capacity, but this result wasn’t considered definitive.

The EMBRACE trial, a Phase II study in heart failure patients, found some changes in cardiac biomarkers. Taken together, human trials exist, but they don’t currently support efficacy claims for heart failure as a general category.

Primary mitochondrial myopathy, Limited evidence, human data: Some

The MMPOWER trial program tested SS-31 in this condition and produced mixed results, without a clear or consistent efficacy signal across the endpoints measured. Human data exists, but it stops short of supporting confident claims of benefit, and further trials would be needed to identify effect size or which patients might respond.

Kidney disease, Emerging evidence, human data: None

This is where the animal literature is deepest, spanning ischemia-reperfusion acute kidney injury, diabetic nephropathy, obstructive nephropathy (UUO), sepsis-induced kidney injury, and atherosclerotic renal artery stenosis. Across these animal models, SS-31 consistently showed protective effects on mitochondrial function and kidney tissue.

No human outcome data exists for any kidney indication, making this a mechanistically promising but entirely preclinical research area.

General longevity, mitochondrial health, and athletic performance, Emerging evidence, human data: None

The proposed mechanism is biologically plausible for broader mitochondrial support in aging or performance contexts, but no dedicated human trials have tested SS-31 in healthy adults, aging populations, or athletes. Claims circulating in longevity and biohacking spaces rely on extrapolation from disease-model research rather than direct evidence in these populations. how we rate evidence

Weight loss, Limited evidence, human data: Very limited

Animal studies across several disease models found no effect on body weight from SS-31 administration. No human weight-loss data exists at all. Current evidence does not support weight loss as a use case, which meaningfully separates SS-31 from GLP-1 drugs it’s sometimes informally compared to. GLP-1 and weight-loss peptides

Notably, researchers across the animal literature repeatedly emphasize that SS-31 shows no measurable effect on healthy or normal mitochondria. This finding is framed as a safety differentiator, meaning the compound appears selective for damaged tissue, not as evidence of a general wellness benefit for people without mitochondrial dysfunction.

Does SS-31 Peptide Cause Weight Loss?

No. Current evidence does not support SS-31 causing weight loss, and this is one of the clearest myths worth correcting directly.

Animal studies cited in the peer-reviewed research review found no effect on body weight across several disease models, including obesity-associated nephropathy, cisplatin-induced acute kidney injury, and diabetic nephropathy. In each case, researchers were tracking body weight as a secondary measure alongside kidney and mitochondrial outcomes, and SS-31 did not move the needle on it. No human weight-loss data exists at all, positive or negative.

Why the confusion exists

SS-31 tends to show up in the same longevity and biohacking conversations as GLP-1 drugs like semaglutide and other metabolic peptides. That shared context (podcasts, peptide forums, “stack” discussions) creates an association that the science doesn’t back up. GLP-1 and weight-loss peptides

A mechanism mismatch, not an unproven benefit

This isn’t a case of “promising but understudied.” SS-31’s proposed mechanism works through stabilizing cardiolipin and reducing electron transport chain leakage inside mitochondria. That pathway has nothing to do with appetite regulation, satiety signaling, or the metabolic pathways GLP-1 drugs act on.

There is no plausible mechanistic link between what SS-31 does in the mitochondria and fat loss or appetite suppression. Anyone using SS-31 with weight loss as a goal is working from a mechanism that doesn’t connect to that outcome, not from evidence that’s merely thin or preliminary.

How Is SS-31 Different From Antioxidant Compounds Like CoQ10 and MitoQ?

Most antioxidant supplements work by mopping up reactive oxygen species (ROS) after they’ve already formed. SS-31 is mechanistically different: research describes it as stabilizing cardiolipin directly within the electron transport chain, which is thought to reduce electron leakage at the source, before ROS byproducts are generated in the first place.

That’s a “prevent the leak” model rather than a “clean up the spill” model.

The reviewed research names several other mitochondria-targeting or mitochondria-supporting compounds in this same conversation, MitoQ, CoQ10, cyclosporin A, and NMN, as comparators. It’s worth being precise about what that means: the source material discusses these compounds only in the context of how SS-31’s mechanism differs from them.

It does not provide head-to-head trial data pitting SS-31 against any of them, nor does it detail their own independent efficacy or safety records. Nothing here should be read as a claim about how well MitoQ, CoQ10, or NMN work on their own; that evidence base simply isn’t part of this research document.

One safety-relevant distinction is specific to SS-31 in the animal studies reviewed: it showed no measurable effect on healthy or normal mitochondria, only on mitochondria already under stress or dysfunction. Researchers flag this as a differentiator from other mitochondria-acting compounds, though the underlying research doesn’t test whether other agents share or lack this same selectivity.

This selectivity is mechanistic, not a performance or wellness claim, and it applies only to the disease-model data described earlier in this article.

The History and Development of ss-31 peptide

SS-31’s story begins not in mitochondrial research but in the study of opioid receptors, where researchers Szeto and Schiller first synthesized the compound.

The “SS” in SS-31 stands for Szeto-Schiller, a naming convention that stuck even after the peptide’s real value turned out to have nothing to do with opioid signaling and everything to do with cardiolipin binding inside the mitochondrial membrane.

Once that mitochondrial mechanism became the focus, Stealth BioTherapeutics took on development, sponsoring the clinical trial program that would eventually carry the molecule through human testing under two other names still seen in older literature and some retail listings: Bendavia and MTP-131. All three names, along with elamipretide, refer to the same underlying compound.

The trial lineage reflects a company testing one molecule across several disease areas rather than a single linear path. TAZPOWER, the Barth syndrome trial published in Genetics in Medicine in 2021, produced the functional results that eventually supported the 2025 FDA approval.

Alongside it, Stealth ran MMPOWER in primary mitochondrial myopathy and EMBRACE plus separate HFrEF and HFpEF trials in heart failure, programs whose mixed-to-negative results sit in contrast to the Barth syndrome outcome and explain why approval stayed narrow rather than expanding across indications.

Parallel to the human trial program, a substantial preclinical literature built out the case for SS-31’s broader mitochondrial effects.

A nephrology research group at Jilin University produced much of the animal-model evidence on kidney protection, while a separate line of work using tafazzin-knockdown mouse models, published in Nature/Scientific Reports, examined cardiac mitochondrial structure directly relevant to Barth syndrome.

This preclinical base predates and runs alongside the human trials, and it’s the reason SS-31’s mechanism was well understood scientifically well before any single indication reached approval.

Barth syndrome treatment options

Dosage and administration

Administration details for SS-31 vary sharply depending on whether the context is the approved drug, a supervised trial, or an animal study. There is no single "protocol" that applies across all of these, and blending them together is one of the more common sources of confusion in online discussion of this peptide.

No legitimate human dosing protocol exists for off-label or self-administered use of SS-31. Dosage in the one approved context is governed by regulatory status and the specific approved indication, not by anything published in a forum, a retailer's product page, or a research paper's animal-dosing table.

The intraperitoneal doses used in mouse and rat studies were designed to answer specific biological questions in those species and were never intended, and are not validated, as a template for human self-administration.

Anyone encountering "research peptide" dosing suggestions online should treat them as unsupported by the evidence summarized here; none of the sources reviewed for this article provide or endorse a self-administration protocol outside of a clinical trial or prescribed treatment setting.

Safety and side effects

Safety in supervised clinical trials

Across the human trials reviewed, the most consistently reported adverse events were injection-site reactions: erythema in 57% of participants, pruritus in 47%, pain in 20%, urticaria in 20%, and irritation in 10%. These were described as mostly mild. No serious adverse reactions or fatalities were reported in the cited trials.

This safety picture comes specifically from supervised, protocol-driven administration, where dosing, sterility, and compound identity were controlled and monitored by trial staff.

Safety of self-sourced “research chemical” use

That safety data does not transfer to peptide purchased online as a “research chemical.” Unregulated sourcing introduces risks that were never present in the trials described above: uncertain purity, non-sterile handling or preparation, and no guarantee that the vial actually contains elamipretide at the labeled concentration, or at all.

None of the reviewed sources studied outcomes from this kind of unsupervised use, so the injection-site-reaction rates and “no serious adverse events” findings above cannot be assumed to apply to it.

The long-term data gap

Even within the supervised-trial context, the safety record is short-term. The trials referenced (TAZPOWER, EMBRACE, the HFrEF/HFpEF programs, MMPOWER) ran for limited durations, and none of the sources reviewed include multi-year human safety follow-up. Whether injection-site reactions persist, resolve, or whether other effects emerge with years of continuous use remains unstudied.

Anyone weighing SS-31’s safety profile should treat “well-tolerated in trials” and “safe long-term” as two separate, unequal claims, only the former is currently supported.

Who should not use SS-31

Legal status

As of 2025, the FDA approved SS-31, marketed under the generic name elamipretide, for Barth syndrome. This is the first mitochondria-targeted peptide to receive full FDA approval for any indication, and the approval is specific to this single rare disease, not a general clearance for mitochondrial dysfunction or peptide use broadly.

That approval didn't happen in isolation. Before full approval, SS-31 held an FDA Rare Pediatric Disease designation for Barth syndrome, a status that typically signals the agency's recognition of unmet need in a small patient population but does not itself authorize marketing or prescribing.

The 2025 approval represents the step beyond that designation, converting a regulatory pathway into an actual approved therapy, still bounded to the one condition.

Why some sources say it's still unapproved

Content describing SS-31 as "not yet FDA-approved" reflects material written before the 2025 decision. That framing was accurate at the time it was published but is now outdated. Readers encountering that claim elsewhere should treat the 2025 Barth syndrome approval as the current status, and understand older pages simply predate it.

What the approval does not cover

The approval does not extend to longevity use, weight loss, athletic performance, or general mitochondrial health support. Every one of those applications remains off-label and investigational, regardless of the mechanistic rationale discussed elsewhere in this article.

A drug approved for one narrow, genetically defined pediatric population carries no regulatory sanction for use by someone without that diagnosis, no matter how the compound is marketed or discussed online.

"Research chemical" sales sit outside this pathway entirely

SS-31 sold online as a research chemical is explicitly labeled by sellers as "Research Use Only, Not for Human or Veterinary Use." That labeling is a legal disclaimer, not a technicality.

It means the product has not gone through the approval process for personal use, carries no oversight on manufacturing or purity for human administration, and exists entirely outside the pathway that produced the Barth syndrome approval. Purchasing it for self-administration sits in that unregulated space regardless of how the product is described in marketing copy. peptide legality and research-chemical risk

A status that can change

Regulatory status is a snapshot, not a permanent fact. Approvals can expand, new designations can be granted, and enforcement postures can shift. Anyone making a decision based on the legal status of SS-31 should verify current FDA records rather than relying on any single article, including this one, as a permanent reference point.

Often used with

In online longevity discussions, SS-31 is frequently mentioned alongside MOTS-c and Humanin, two other mitochondrial-derived peptides grouped under the same "mitochondrial and metabolic" longevity category in source material. This shared category reflects marketing and discussion patterns, not a tested combination. No clinical protocol exists for sequencing or stacking SS-31 with MOTS-c, and no washout period between the two has been established in any source reviewed. Evidence for this practice

Frequently asked questions